Cy5.5 NHS Ester (Non-Sulfonated): Next-Gen Near-Infrared Fluorescent Dye for Biomolecule Labeling

Principle and Setup: Harnessing Near-Infrared Chemistry for Superior Biomolecule Labeling

Cy5.5 NHS ester (non-sulfonated) is an advanced near-infrared fluorescent dye for biomolecule labeling, prized for its ability to conjugate efficiently with peptides, proteins, and oligonucleotides containing primary amino groups. The N-hydroxysuccinimide (NHS) ester moiety provides highly selective reactivity with amines, forming stable amide bonds that preserve biomolecular function while introducing a bright, photostable near-infrared signal. With an excitation maximum at 684 nm and emission at 710 nm (the classic cy5 5 excitation emission window), Cy5.5 NHS ester enables researchers to visualize targets deep within tissues with minimal background autofluorescence — a distinct advantage over visible-range dyes.

APExBIO supplies this reagent as a solid, stable for up to 24 months at -20°C in the dark. Its high solubility in DMF and DMSO (≥35.82 mg/mL in DMSO) supports rapid dissolution and immediate use. However, because aqueous solubility is low, initial dissolution in organic co-solvent is mandatory before reaction in buffered aqueous solutions. This workflow is central for successful fluorescent dye for protein conjugation and robust amino group labeling reagent applications.

Step-by-Step Workflow: Protocol Enhancements for Optimal Labeling

1. Preparation of Stock Solution

• Weigh the desired amount of Cy5.5 NHS ester (non-sulfonated) (SKU A8103) under low-light conditions to prevent photobleaching.
• Dissolve immediately before use in dry DMSO or DMF to prepare a concentrated stock (e.g., 10 mg/mL). Vortex or pipette gently to aid dissolution.
• Avoid long-term storage in solution; the NHS ester hydrolyzes rapidly in the presence of moisture.

2. Biomolecule Preparation

• Dissolve the target protein, peptide, or oligonucleotide in a suitable aqueous buffer (typically 0.1 M sodium bicarbonate, pH 8.3–8.5) to ensure deprotonation of amines and maximize conjugation efficiency.
• Ensure absence of competing primary amine buffers (e.g., avoid Tris or glycine) and reducing agents, which can quench labeling.

3. Conjugation Reaction

• Slowly add the Cy5.5 NHS ester solution to the biomolecule under gentle stirring.
• Maintain a typical molar ratio of dye:biomolecule between 3:1 and 10:1, optimizing for labeling density and biological activity.
• Incubate at room temperature for 30–60 minutes, protected from light.

4. Purification and Quality Control

• Quench excess NHS ester with ethanolamine (10 mM final) or by extensive dialysis.
• Remove unconjugated dye by gel filtration (Sephadex G-25), spin column desalting, or repeated centrifugal filtration (10–30 kDa MWCO, depending on biomolecule size).
• Quantify labeling degree using absorbance at 684 nm (ε ≈ 250,000 M⁻¹cm⁻¹ for Cy5.5) and the protein’s own absorbance at 280 nm.

For a protocol deep-dive and advanced troubleshooting, the article "Cy5.5 NHS Ester: Advanced Near-Infrared Fluorescent Dye for Biomolecule Labeling" offers hands-on workflow enhancements and comparative insights.

Advanced Applications and Comparative Advantages

In Vivo and Deep-Tissue Imaging

The defining feature of Cy5.5 NHS ester (non-sulfonated) is its suitability for in vivo fluorescence imaging and deep-tissue optical imaging of tumors. Its long-wavelength excitation/emission (684/710 nm) minimizes tissue scattering and autofluorescence, resulting in greater signal-to-noise ratios in small animal models and clinical samples. Peer-reviewed studies demonstrate its use for tumor margin delineation, pharmacokinetic tracing, and multiplexed imaging in live models ("Cy5.5 NHS Ester (Non-Sulfonated): Benchmarks for Near-Infrared Imaging"). In the context of nanomedicine, Cy5.5-labeled biomolecules have enabled real-time tracking of therapeutic distribution and cellular uptake, providing critical feedback for optimizing drug delivery systems.

Nanoplatforms and Neuromodulation Research

Recent breakthroughs in neuromodulation and nanotechnology—such as the work of Li et al. (Ultrasound-Triggered Biomimetic Piezo-Nanoplatforms for Non-Invasive Epilepsy Treatment)—leverage near-infrared dyes like Cy5.5 for precise localization and tracking of functional nanostructures in the brain. These tumor imaging agent and bio-conjugation studies highlight Cy5.5 NHS ester’s compatibility with complex platforms, including piezoelectric nanoparticles and hybrid materials. By coupling Cy5.5 NHS ester-labeled peptides or antibodies to surface-engineered nanocarriers, researchers can monitor biodistribution and therapeutic efficacy in real time, supporting the development of non-invasive, targeted interventions.

Multiplexed and Cell-Based Assays

For fluorescent labeling in molecular biology, Cy5.5 NHS ester (non-sulfonated) proves invaluable in multiplexed cell assays, cytotoxicity screens, and flow cytometry, as detailed in "Cy5.5 NHS Ester (Non-Sulfonated): Reliable Labeling for Advanced Cell Assays". Its spectral separation from visible fluorophores enables simultaneous detection of multiple targets without cross-talk, while its robust conjugation chemistry ensures consistent labeling and quantitation.

Troubleshooting and Optimization: Maximizing Signal and Specificity

Common Challenges & Solutions

• Low Labeling Efficiency: Confirm the use of amine-free buffers and freshly prepared dye; increase the molar excess of dye if necessary. Ensure pH remains between 8.3-8.5 during conjugation.
• Solubility Issues: Always dissolve Cy5.5 NHS ester in dry organic solvent (DMSO or DMF) immediately before use. Avoid exposure to aqueous solutions until mixing with the biomolecule.
• High Background or Non-Specific Binding: Thoroughly remove unreacted dye via gel filtration or dialysis. Validate specificity with appropriate negative controls and secondary purification if needed.
• Photobleaching: Conduct all steps under subdued light and store conjugates protected from light. Aliquot dye stocks to minimize freeze-thaw cycles.
• Batch-to-Batch Variation: Quantify the degree of labeling spectrophotometrically for each batch and optimize dye:biomolecule ratios as needed.

For additional troubleshooting and peer-based Q&A, the article "Reliable Cell Assays with Cy5.5 NHS Ester (Non-Sulfonated)" offers scenario-driven solutions and practical tips.

Quantitative Performance Metrics

• Degree of Labeling (DOL): Typical DOL for proteins ranges from 2–5 Cy5.5 molecules per antibody or protein monomer, balancing brightness and biological activity.
• Signal-to-Noise (S/N): In in vivo tumor imaging, Cy5.5 NHS ester-labeled antibodies demonstrate S/N improvements of 5x or greater compared to visible-range dyes, enabling clearer tumor boundary visualization (see reference).
• Stability: Labeled conjugates retain >90% fluorescence after 7 days at 4°C in the dark, supporting extended studies.

Future Outlook: Cy5.5 NHS Ester in Precision Diagnostics and Therapeutics

As molecular imaging and nanomedicine converge, Cy5.5 NHS ester (non-sulfonated) is poised to underpin the next generation of near-infrared fluorescence imaging strategies. Its application extends beyond traditional tumor imaging to innovative neuromodulation platforms, real-time biodistribution studies, and personalized diagnostics. Integration with piezoelectric nanoplatforms and multiplexed molecular probes is redefining the landscape for non-invasive, precision-guided therapeutics—exemplified by the work of Li et al. (2025), where near-infrared tracking is essential for translational neuroscience.

For researchers ready to elevate their imaging and labeling workflows, Cy5.5 NHS ester (non-sulfonated) from APExBIO delivers a trusted, performance-validated solution. By drawing on best practices and the latest literature, including strategic perspectives from "Beyond Brightness: Mechanistic and Strategic Frontiers for Cy5.5 NHS Ester", scientists can optimize every stage of labeling, imaging, and translational research.